Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue

Exclusion Criteria

• •1. History of inflammatory bowel disease or active inflammatory condition of the GI tract
• •2. History of significant gastrointestinal bleeding
• •3. Current medically-indicated use of warfarin or heparin or other anticoagulant medications associated with increased risk for bleeding following mucosal biopsy (e.g., daily high dose aspirin \[\>81 mg\], non-steroidal anti-inflammatory drugs \[NSAIDs\], or Pradaxa®)
• •4. Use of systemic immunomodulatory medications within 4 weeks of enrollment
• •5. Use of rectally administered medications within 4 weeks of enrollment
• •6. Use of product containing nonoxynol-9 within 4 weeks of enrollment
• •7. Use of any investigational products within 4 weeks of enrollment
• •8. Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease.
• •9. Active rectal infection (GC, Chlamydia, HSV). Participants screening positive for GC/CT at the time of endoscopy will be excluded from analysis (and replaced).
• •For participants not undergoing a concurrent endoscopic procedure for indication unrelated to this study:
• •10. Hct \<36%
• •11. Platelet count \<150/mm3
• •12. International normalised ratio blood test \> 1.2